Variability Within The Dopamine System

Of the six most common neurotransmitters, dopamine is probably the one people know the most about. Dopamine is involved in controlling the reward and pleasure system in the brain. It allows us to recognize rewards and helps give us the ability to go after them. Learning, behavior, and cognition are also affected by dopamine levels. As with anything, if you have an imbalance, then bad things can happen. Parkinson’s disease can be caused by low dopamine amounts. People who have low dopamine levels can be addicted to substances easier.

Some dopaminergic (i.e., dopamine-releasing) neurons run from the substantia nigra to the corpus striatum; their loss gives rise to the clinical manifestations of Parkinson's Disease (Korczyn 1994); others, involved in the rewarding effects of drugs and natural stimuli, run from the mesencephalon to the nucleunucleus accumbens.

Dopamine receptors are g-protein coupled receptors (GPCRs) which exist in two families of subtypes. Activation of D1-like receptors (D1 and D5) induce adenylyl cyclase activity which increases levels of cAMP and subsequent PKA activation. Conversely, D2-like receptors (D2, D3 and D4) inhibits production of cAMP and subsequently reduces PKA activation (Beaulieu J-M and Gainetdinov RR, 2011).

In the field of genetics, the study of the effect of various genes is imperative in translation and interpretation. As genetic coding influences phenotypic expression, the analysis of specific genes and any polymorphisms are relevant in a clinical setting. One such example is that of personality traits, which are believed to be influenced by specific neurotransmitters, known as catecholamines. Catecholamines are chemicals released by the adrenal glands in response to stress, and operate dually as hormones and neurotransmitters within the body. Commonly, catecholamines mediate functions within the central nervous system, including those of emotional responses and motor control. Inclusive of dopamine, epinephrine and norepinephrine, the

What do schizophrenia, Parkinson’s disease, bipolar disorder, and cocaine all have in common? It turns out they are all linked to the role of the dopamine transporter (DAT), which is an integral membrane protein responsible for the reuptake of dopamine from the synapse. Drugs that bind to DAT to prevent the reuptake of dopamine are used to treat the diseases mentioned above, among others. However, cocaine, which is also a DAT blocker, leads to profoundly negative effects, such as addiction and psychomotor stimulation. Understanding how different DAT blockers produce distinct behavioral and chemical responses could be the key to developing better drugs to treat dopaminergic disorders and also addiction to DAT blockers like cocaine.

Unraveling the code to PD Parkinson's disease (PD) is a neurodegenerative disease that directly affects the central nervous system, leaving the victim with debilitating impairment of their motor function. Several decades of research and advancement in technology has led scientists, physicians, and patients to the latest possible cure for Parkinson's disease, stem cells. PD is known to affect the midbrain, where the substantia nigra produces dopamine that directly affects the autonomic nervous system. Studying the nerve cells in this region of the brain and culturing them to become IPS (Induced-pluripotent stem) cells, we may better understand the mechanisms and intermediate steps that lead to their degeneration. These alternative pathways

(B): The 2016 Cell Biology of the Neuron
Gordon Research Conference in Waterville Valley, NH is devoted to outstanding discoveries in neural development, function, regeneration as well as diseases. Neuronal cell biology has emerged as one of the most exciting and rapidly moving fields in contemporary biology. This field is experiencing a revolution in imaging technology and at the same time, powerful molecular and

Dampening serotonergic activity with 5-HT1A can prevent the exocytotic release of dopamine from serotonergic terminals17,26.Though it is thought that DA is released from serotonergic innervations from all the brain areas including the hippocampus, prefrontal cortex, substantia nigraand striatum, the striatum is believed to be responsible for LID because of the source of the major release of DA from L-DOPA from the abundant serotonergic innervation24,25.Therefore, my proposal includes reducing dysregulated serotonergic activity specifically in the striatum with local striatal administration of 5-HT1A agonist in a PD mouse model. Whereas most of the other studies focus on treating dyskinesia with 5-HT1A agonist when LID is already developed in PD17,20,my research proposal will target on the prevention of dyskinesia while giving a L-DOPA treatment for PD. For this purpose, I hypothesize that co-administration of a specific5-HT1Aagonist with L-DOPA may reduce the dysregulation of dopamine and could potentially produce the effectsof L-DOPA treatment for PD without the appearance of

Parkinson’s disease is affected by the degeneration of dopaminergic neurons which is responsible to produce dopamine. Dopaminergic neurons have their cell bodies in substantia nigra pars compacta (SNpc) in basal ganglia (O’Sullivan and Schmitz, 2007). Basal ganglia are a collection of interconnected gray matter nuclear masses deep within the brain”. These gray matter masses are caudate, putamen, globus pallidus, subthalamic nucleus and the substantia nigra. Basal ganglia receive its input through striatum (O’Sullivan and Schmitz, 2007).

While the cause of primary PD is has not been determined the neuropathology of PD is well understood. The midbrain contains the basal ganglia and the thalamus. Both of these have excitatory and inhibitory neural pathways that form two pathways: (1) and excitatory loop that is a direct path and (2) and inhibitory path that is indirect (Dauer & Przedborski, 2003). In PD there is initially a loss of dopamine producing neurons in the excitatory loop and the appearance of Lewy bodies throughout the brain. The loss of these dopaminergic neurons indicates that in PD the defining feature is a substantial decrease in the neurotransmitter dopamine (which occurs in the nirgrostriatal brain tract; (Dauer & Przedborski, 2003).

Dopamine is a neurotransmitter in the brain that is extremely important in the functions of movement, memory, pleasurable reward, behavior and cognition, attention, inhibition of prolactin production, sleep, mood, and learning (Mandal, 2015). There are consequences of having too much or too little of dopamine in the body; it can cause several disease conditions such as Parkinson’s disease and drug addiction. According to Dr Anaya Mandal, “dopamine is produced in the dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain, the substantia nigra pars compacta, and the arcuate nucleus of the hypothalamus”. Basal ganglia is part of the brain that controls and regulates movement (Mandal, 2015). It helps a number of functions such

In the brain, dopamine operates as a neurotransmitter: a chemical released by neurons to send signals to other nerve cells. The brain contains several different dopamine pathways. Dopamine plays a role in regulating information from different areas of the brain. Dopamine mediates pleasure within the brain. It is released during pleasurable situations, so that one experiences delight in activities. Levels of dopamine in the brain help revamp memory. It also helps in concentration and reflex. In addition, it regulates control of motor functions, and is said to be crucial to learning.

This further shows how this gene and this particular allele is considered one of the strongly associated candidates in ADHD. The dopamine transporter DAT1 is generally expressed in striatal regions, a set of brain regions that have been shown to have an increased binding of DAT associated with the presence of the 9R allele (van der Meer et al., 2017).

Usiello, Alessandro, et al. "Distinct Functions Of The Two Isoforms Of Dopamine D2 Receptors." Nature

What is known is that the forebrain roof plate starts to develop soon after neurulation, when roof plate cells, which are the first cohort of cell to exit the cell cycle (Kahane and Kalcheim, 1998) begin to form a thin monolayer. This is the time point when the roof plate starts expressing multiple signaling molecules such as members of the Bmp, Wnt and Fgf families exhibiting different gradients along the anterior-posterior axis (Crossley et al., 2001; Furuta et al., 1997; Shimogori et al., 2004). Roof plate development is a complex process and requires the activity of the same set of signaling molecules which later pattern the dorso-medial structures in the forebrain. Evidence gathered primarily from studies in the chick embryo suggest that correct dorsal-ventral patterning of the forebrain is a pre-requisite for subsequent establishment of roof plate identity. In fact the dorsal-ventral identity of the forebrain is acquired as early as the neural fold stage where Wnt signaling first imparts dorsal character to the forebrain cells which otherwise would exhibit ventral characteristics. However, Wnt signaling alone can only impart the initial dorsal forebrain characteristics manifested as the expression of certain markers. Nonetheless, Wnt signaling together with Fgf8 induces the definitive dorsal forebrain characteristics (Gunhaga et